This market research report has been designed to help both sponsors and providers in the bioanalytical lab space stay current with market dynamics and anticipate potential changes that may affect future resource requirements, outsourcing strategy developments, organizational benchmarking, and more.
Comprehensive contract development. Reliable cGMP manufacturing. Gain a competitive advantage in both by choosing Patheon for your biopharmaceuticals and biosimilars. You’ll have access to end-to-end, fully integrated services for both drug substances and drug products, delivered on time and on budget. A simplified supply chain that accelerates development and keeps you ahead in the rapidly changing world of biologics.
Get more results with the CHO Media Development Kit, which allows you to create a formulation development strategey that fits with your project timeline, resources, and goals.
The Unscrambler X Process Pulse real-time process monitoring solution gives manufacturers the visibility and responsiveness needed in today's complex environments.
Considering that 90% of drug candidates have bioavailability issues, making sure your program is prepared for all phases of clinical trials from the very start is the fast way forward. Patheon Solubility Enhancement Services approaches BCS II and IV drug substance solubility issues a fundamentally different way that identifies the solubility enhancement technologies most likely to work before you get started. That helps eliminate rework and worry later on.
Magnosphere™ is a superparamagnetic particle for in vitro diagnostics and bio research applications.
The Allegro STR bioreactor family combines Pall’s bioprocess engineering expertise, cell culture know-how and our drive for quality into a series of single-use bioreactors that deliver consistent and scalable cell culture performance across the range. The Allegro STR bioreactor family has a direct bottom-driven impellor allowing power inputs up to 0.25 W/kg, resulting in high oxygen transfer rates and short mixing times.
The new Eppendorf incubator shakers, Innova 42 & 42R with added refrigeration, provide the convenience of "set it and forget it" programming, for automating multiple changes to operating parameters.
Althea’s complete range of drug Process Development capabilities offers the tools to address your needs. We develop processes for producing small quantities of proteins for early testing or establish robust, reliable and scalable processes that enable a strong commercial advantage. Althea also provides access to a proprietary drug delivery platform, called Crystalomics® technology, for the development of alternative drug delivery formulations of second generation drug substances.
PODs can be utilized in a multitude of applications including: monoclonal antibodies, vaccine or recombinant proteins, personalized medicines, cell and gene therapy and even laboratory use. The utilization of single-use processing equipment within the POD creates the most flexible production platform available.
|
|
|
|
|
|
|
|
|